Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3

Bibliographic Details
Main Author:	The Editors
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037903/?tool=EBI

Similar Items

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.
by: PLOS ONE Editors
Published: (2022-01-01)

Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.
by: Toni M Brand, et al.
Published: (2013-01-01)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
by: Carla De Giovanni, et al.
Published: (2021-07-01)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Kong, A, et al.
Published: (2008)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Anthony Kong, et al.
Published: (2008-08-01)

Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.
by: Saghir Akhtar, et al.
Published: (2015-01-01)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023-03-01)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
by: Nathan Griffin, et al.
Published: (2020-09-01)

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
by: Snježana Mikuličić, et al.
Published: (2024-02-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment
by: Matthias Parrini, et al.
Published: (2018-12-01)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
by: Ilana Schlam, et al.
Published: (2021-05-01)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
by: Desh Deepak Singh, et al.
Published: (2022-12-01)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
by: Xue Yang MSc, et al.
Published: (2020-10-01)

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
by: James W Peacock, et al.
Published: (2018-02-01)

Corrigendum: ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
by: Snježana Mikuličić, et al.
Published: (2024-02-01)

Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling
by: Mohamed R. Akl, et al.
Published: (2015-01-01)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
by: Ibrahim H. Kankia, et al.
Published: (2021-04-01)

Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
by: Dayana Pérez-Martínez, et al.
Published: (2022-07-01)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
by: Daniela Miladinova
Published: (2023-03-01)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
by: Jack D. Godfrey, et al.
Published: (2022-08-01)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
by: Andreia Gameiro, et al.
Published: (2021-03-01)

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
by: Marie-Anne Goyette, et al.
Published: (2023-12-01)

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
by: Robert Jenke, et al.
Published: (2020-12-01)

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
by: Marie-Anne Goyette, et al.
Published: (2018-05-01)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
by: Donatella Romaniello, et al.
Published: (2020-08-01)

A novel C-terminal domain of RecJ is critical for interaction with HerA in Deinococcus radiodurans
by: Kaiying eCheng, et al.
Published: (2015-11-01)

Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity
by: Belén Mezquita, et al.
Published: (2014-02-01)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
by: Martina S. J. McDermott, et al.
Published: (2019-02-01)

Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects
by: Lie Chen, et al.
Published: (2023-11-01)

Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer
by: Alyson Yoder, et al.
Published: (2022-01-01)

The C-terminal transactivation domain of MITF interacts promiscuously with co-activator CBP/p300
by: Alexandra D. Brown, et al.
Published: (2023-09-01)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
by: Sun Y, et al.
Published: (2021-09-01)

Retraction: A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells Differentiation.
by: PLOS ONE Editors
Published: (2022-01-01)

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer
by: Croce Kimiko, et al.
Published: (2009-05-01)

The Refugee Woman and her Family
by: Eva Allmen
Published: (1987-02-01)

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
by: Guangjian Yang, et al.
Published: (2022-03-01)

Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4)
by: Marianne Nordlund Broughton, et al.
Published: (2017-06-01)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)